The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Genzyme; Roche; Sanofi; Shire; Tesaro
Consulting or Advisory Role - Baxalta; Celgene; H3 Biomedicine; Quantum Design Europe; Shire
Speakers' Bureau - Celgene; Sanofi; Shire
Research Funding - Agios (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); Merrimack (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; H3 Biomedicine; Merck; Sanofi
A phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) patients (pts).
 
Teresa Macarulla Mercade
No Relationships to Disclose
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Merck
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); E-therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Menarini (Inst); Merck (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
 
Binu John
Consulting or Advisory Role - Bayer; Eisai; Gilead Sciences
Research Funding - Bayer; BMS Brazil; H3 Biomedicine
 
John Charles Morris
Speakers' Bureau - Boehringer Ingelheim; Merck
Patents, Royalties, Other Intellectual Property - National Institutes of Health patent
 
Michael B. Sawyer
Honoraria - Baxter; Bristol-Myers Squibb; Celgene; Fresenius Kabi; Ipsen; LEO Pharma; Merck; Novartis; nutricia; pfizer; Sanofi; Shire; Taiho Pharmaceutical
Consulting or Advisory Role - Celgene; Immuneering; LEO Pharma; Nutricia; Pfizer; Yinuoke
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - My lab discovered that all the competitive tyrosine kinase inhibitors such as sunitinib and gefitinib have additional pharmacological properties. This additional pharmacologic property causes intestinal epithelial cells to active their chloride channels l
Travel, Accommodations, Expenses - Amgen; Ipsen; LEO Pharma; Novartis Canada Pharmaceuticals Inc; Nutricia; pfizer
 
Wei Peng Yong
Honoraria - ASLAN Pharmaceuticals; BMS Brazil; MSD
Speakers' Bureau - Lilly
Travel, Accommodations, Expenses - Pfizer
 
Martin Gutierrez
Stock and Other Ownership Interests - COTA
Consulting or Advisory Role - Bayer; Karyopharm Therapeutics; Lilly
Speakers' Bureau - Bristol-Myers Squibb; Foundation One Inc; Lilly; Merck
Research Funding - Abbvie (Inst); Acceleron Pharma (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Esanex (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Seagen (Inst); Tesaro (Inst); TG Therapeutics (Inst)
 
Thomas Benjamin Karasic
Research Funding - Celgene; H3 Biomedicine; Syndax; Taiho Pharmaceutical
 
Bruno Sangro
Consulting or Advisory Role - Adaptimmune; AstraZeneca; Bayer; Bristol-Myers Squibb; BTG; H3 Biomedicine; Ipsen; Lilly; Merck; Onxeo; Sirtex Medical
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Sirtex Medical
Research Funding - Bristol-Myers Squibb (Inst); Sirtex Medical (Inst)
 
Yang Sheng-Shun
Consulting or Advisory Role - Abbvie; Gilead Sciences
Speakers' Bureau - Abbvie; Gilead Sciences; MSD
 
Carleen Gentry
Employment - H3 Biomedicine
 
Amy Kim
Employment - H3 Biomedicine
 
Pavan Kumar
Employment - H3 Biomedicine
 
Crystal MacKenzie
Employment - H3 Biomedicine
Travel, Accommodations, Expenses - H3 Biomedicine
 
Nathalie Rioux
Employment - H3 Biomedicine
 
Joanne Schindler
Employment - H3 Biomedicine
Leadership - H3 Biomedicine
 
Anand Selvaraj
Employment - H3 Biomedicine
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Novartis